Stay updated on ZN-c3 in Platinum-Resistant Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the ZN-c3 in Platinum-Resistant Ovarian Cancer Clinical Trial page.

Latest updates to the ZN-c3 in Platinum-Resistant Ovarian Cancer Clinical Trial page
- Check3 days agoChange DetectedAdded the new study title A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer (MUIR) and expanded the description of the Phase 1b study design, including Part 1 and Part 2, dose escalation and expansion with bevacizumab. Updated the page to Completed status with an enrollment target of 172 and a primary completion date of 2028-06-30, replacing the previous version.SummaryDifference3%

- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedRevision v3.5.0 was added and v3.4.3 was removed.SummaryDifference0.0%

- Check32 days agoChange DetectedRevision: v3.4.3 is now displayed, replacing the previous v3.4.2.SummaryDifference0.0%

- Check61 days agoChange DetectedFallopian tube cancer was added to the study's conditions, and the page revision was updated to v3.4.2 (v3.4.1 was removed).SummaryDifference0.1%

- Check68 days agoChange DetectedRevision: v3.4.1 replaces Revision: v3.4.0 on the page, which is a minor update to the revision label and does not affect study data or content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check75 days agoChange DetectedAdded a glossary display, the 'Last Update Submitted that Met QC Criteria' label, 'No FEAR Act Data' notice, and Revision: v3.4.0. Removed the older items 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and Revision: v3.3.4.SummaryDifference0.2%

Stay in the know with updates to ZN-c3 in Platinum-Resistant Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ZN-c3 in Platinum-Resistant Ovarian Cancer Clinical Trial page.